NextGenNK Press Releases 2021
Oncternal Therapeutics Joins NextGenNK Competence Center
On November 3 2021 Oncternal Therapeutics announced their entry to NextGenNK. “We look forward to strengthening our partnership with the world-renowned Karolinska Institutet and joining other industry and academic partners in developing the next generation of cell therapies,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
PRESS RELEASE BY: ONCTERNAL THERAPEUTICS 2021-11-03
XNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma
XNK Therapeutics AB (“XNK”) announced on July 1st 2021 that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab). XNK and Sanofi are partners in NextGenNK.
PRESS RELEASE BY: XNK THERAPEUTICS 2021-07-01
Sorrento and KI researchers enter a collaborative agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer Cells
Sorrento Therapeutics, Inc. announced their entry into an additional collaborative agreement with research groups at Karolinska Institutet, aimed at producing novel cell-based therapeutics using NK cells derived from induced pluripotent stem cells (“iPSCs”). Sorrento and KI are collaborative partners in NextGenNK.
PRESS RELEASE BY: SORRENTO THERAPEUTICS INC. 2021-06-04
XNK partners with KI on Phase II study in MM with support from Sanofi
XNK Therapeutics AB (“XNK”) announce their entry into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center.